Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In...

BenzingaFeb 12 06:51 ET

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

GlobeNewswireJan 30 16:01 ET

Aclaris Therapeutics Highlights Drug Progress and Financial Strength

TipRanksJan 13 07:58 ET

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Analyst UpgradesDec 23, 2024 13:41 ET

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

BenzingaDec 23, 2024 10:29 ET

Aclaris Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow JonesDec 23, 2024 07:04 ET · Ratings